Cited by 412Systemic Lupus Erythematosus ResearchSystemic Sclerosis and Related DiseasesVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus

Ruiz-Irastorza, G, Egurbide, M-V, Pijoan, J-I, Garmendia, M, Villar, I, Martinez-Berriotxoa, A, Erdozain, J-G, Aguirre, C·2006·Lupus

DOI 10.1177/0961203306071872

Open this paper in CoChat — free account

Abstract

Antimalarials have shown beneficial effects on systemic lupus erythematosus (SLE) activity. Our aim was to investigate whether antimalarials protect against thrombosis and influence survival in SLE patients. A prospective cohort including 232 patients with SLE were included in the study at the time of lupus diagnosis. End points were documented thrombosis and death due to any cause. A Cox regression-multiple-failure time survival analysis model was fitted to establish the effect of antimalarials on the development of thrombosis. Kaplan-Meier survival curves and propensity score adjusted-Cox regression analysis were performed to investigate the effect of antimalarials use on survival. Of our subjects, 204 patients (88%) were women. 230 patients (99%) were white. 150 patients (64%) had ever received antimalarials. Median time on antimalarials was 52 months (range three to 228 months). The Cox multiple-failure time survival analysis showed that taking antimalarials was protective against thrombosis (HR 0.28, 95%CI 0.08-0.90), while aPL-positivity (HR 3.16, 95%CI 1.45-6.88) and previous thrombosis (HR 3.85, 95%CI 1.50-9.91) increased the risk of thrombotic events. Twenty-three patients died, 19 of whom (83%) had never received antimalarials. No patient treated with antimalarials died of cardiovascular complications. Cumulative 15-year survival rates were 0.68 for never versus 0.95 for ever treated patients ( P < 0.001). Age at diagnosis and propensity score-adjusted HR for antimalarials ever versus never users was 0.14 (95%CI 0.04-0.48). Our study shows a protective effect of antimalarials against thrombosis and an increased survival of SLE patients taking these drugs. These data support the routine use of antimalarials in all patients with SLE.

Integrity signals

Registry

Crossref · 10.1177/0961203306071872

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Age-specific Incidence Rates of Myocardial Infarction and Angina in Women with Systemic Lupus Erythematosus: Comparison with the Framingham Study
Manzi, S., Meilahn, E. N., Rairie, J. E., Conte, C. G., Medsger, T. A., Jansen-McWilliams, L., D’Agostino, R. B., & Kuller, L. H. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009122 · Cited by 1,831
Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus
Roman, M. J., Shanker, B., Davis, A., Lockshin, M. D., Sammaritano, L. R., Simantov, R., Crow, M. K., Schwartz, J. E., Paget, S. A., Devereux, R. B., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035471 · Cited by 1,422
Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Mejía, J. C., Aydintug, A. O., Chwalinska-Sadowska, H., de Ramón, E., et al. (2003) · Medicine · doi:10.1097/01.md.0000091181.93122.55 · Cited by 1,377
Premature Coronary-Artery Atherosclerosis in Systemic Lupus Erythematosus
Asanuma, Y., Oeser, A. M., Shintani, A., Turner, E. L., Olsen, N. J., Fazio, S., Linton, M. F., Raggi, P., & Stein, C. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035611 · Cited by 889
Sequential Therapies for Proliferative Lupus Nephritis
Contreras, G. N., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O'Nan, P., & Roth, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031855 · Cited by 815
Activation of the interferon‐α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease
Kirou, K. A., Lee, C., George, S., Louca, K., Peterson, M. G. E., & Crow, M. K. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21031 · Cited by 702
A Randomized Study of the Effect of Withdrawing Hydroxychloroquine Sulfate in Systemic Lupus Erythematosus
The Canadian Hydroxychloroquine Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199101173240303 · Cited by 676
Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis
Illei, G. G., Austin, H. A., Crane, M., Collins, L., Gourley, M. F., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Steinberg, A. D., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-4-200108210-00009 · Cited by 487
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison.
Gladman, D. D., Goldsmith, C. H., Urowitz, M. B., Bacon, P. A., Fortin, P. R., Ginzler, E. M., Gordon, C., Hanly, J. G., Isenberg, D. A., Petri, M., et al. (2000) · PubMed · Cited by 477
Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
Petri, M., Roubenoff, R., Dallal, G. E., Nadeau, M., Selhub, J., & Rosenberg, I. H. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03032-2 · Cited by 418
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual
Fessler, B. J., Alarcón, G. S., McGwin, G., Roseman, J. M., Bastian, H. M., Friedman, A., Baethge, B. A., Vilá, L. M., Reveille, J. D., & for the LUMINA Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21039 · Cited by 377
Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis
Husted, J., Gladman, D., Farewell, V. T., & Cook, R. J. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200104)45:2 · Cited by 345
A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome
Erkan, D. (2002) · Rheumatology · doi:10.1093/rheumatology/41.8.924 · Cited by 330
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis
Petri, M., Lakatta, C., Magder, L., & Goldman, D. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90151-1 · Cited by 323
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events
Toloza, S., Uribe, A. G., McGwin, G., Alarcón, G. S., Fessler, B. J., Bastian, H. M., Vilá, L. M., Wu, R., Shoenfeld, Y., Roseman, J. M., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20622 · Cited by 319
Mortality and causes of death in systemic lupus erythematosus
Trager, J., & Ward, M. M. (2001) · Current Opinion in Rheumatology · doi:10.1097/00002281-200109000-00002 · Cited by 264
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis
Petri, M. (1996) · Lupus · doi:10.1177/0961203396005001051 · Cited by 259
Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice
Edwards, M. H., Pierangeli, S., Liu, X., Barker, J. H., Anderson, G., & Harris, E. N. (1997) · Circulation · doi:10.1161/01.cir.96.12.4380 · Cited by 250
Hydroxychloroquine Reverses Platelet Activation Induced by Human IgG Antiphospholipid Antibodies
Espinola, R., Ghara, A., Harris, E., & Pierangeli, S. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613033 · Cited by 240
PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
Bruce, I. N., Gladman, D. D., & Urowitz, M. B. (2000) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70138-1 · Cited by 240
High Impact of Antiphospholipid Syndrome on Irreversible Organ Damage and Survival of Patients With Systemic Lupus Erythematosus
Ruiz‐Irastorza, G., Egurbide, M.-V., Ugalde, J., & Aguirre, C. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.1.77 · Cited by 238
Self-citation
Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups
Mok, C. C., Tang, S. S. K., To, C. H., & Petri, M. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21224 · Cited by 237
Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids
Wallace, D. J., METZGER, A. L., Stecher, V. J., Turnbull, B. A., & Kern, P. A. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90345-e · Cited by 230
Mannose-Binding Lectin Variant Alleles and the Risk of Arterial Thrombosis in Systemic Lupus Erythematosus
Øhlenschlæger, T. F., Garred, P., MADSEN, H. O., & Jacobsen, S. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033122 · Cited by 197
Thrombosis and Systemic Lupus Erythematosus: The Hopkins Lupus Cohort Perspective
Petri, M. (1996) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749609069986 · Cited by 176
Economic consequences of the progression of rheumatoid arthritis in Sweden
Kobelt, G., Eberhardt, K., J�nsson, L., & J�nsson, B. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199902)42:2 · Cited by 167
Biochemical characterization of ADP-ribose polymer metabolism in SLE
Chen, H.-Y., Pertusi, R. M., Kirkland, J., Rubin, B. R., & Jacobson, E. L. (1996) · Lupus · doi:10.1177/096120339600500105 · Cited by 162
Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus.
Ibañez, D., Urowitz, M. B., & Gladman, D. D. (2003) · PubMed · Cited by 161
Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy.
Borba, E. F., & Bonfá, E. (2001) · PubMed · Cited by 145
Systemic Lupus Erythematosus and Accelerated Atherosclerosis
Hahn, B. H. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038168 · Cited by 136
Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort{
Molad, Y., Gorshtein, A., Wysenbeek, A. J., Guedj, D., Majadla, R., Weinberger, A., & Amit-Vazina, M. (2002) · Lupus · doi:10.1191/0961203302lu203ra · Cited by 134
Controlled trial with chloroquine diphosphate in systemic lupus erythematosus
Meinão, I., Sato, E. I., Andrade, L. E. C., Ferraz, M., & Atra, E. (1996) · Lupus · doi:10.1177/096120339600500313 · Cited by 131
Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events
Ho, K. T., Ahn, C. W., Alarcón, G. S., Baethge, B. A., Tan, F. K., Roseman, J., Bastian, H. M., Fessler, B. J., McGwin, G., Vilá, L. M., et al. (2005) · Rheumatology · doi:10.1093/rheumatology/kei014 · Cited by 128
Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus.
Tam, L., Gladman, D. D., Hallett, D. C., Rahman, P., & Urowitz, M. B. (2000) · PubMed · Cited by 127
Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?
Wallace, D. J. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301219 · Cited by 124
The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation?
Merrill, J. T., & Lahita, R. G. (1996) · Lupus · doi:10.1177/096120339600500103 · Cited by 118
The Relevance of Antimalarial Therapy with Regard to Thrombosis, Hypercholesterolemia and Cytokines in SLE
Wallace, D. J., Linker‐Israeli, M., METZGER, A. L., & Stecher, V. J. (1993) · Lupus · doi:10.1177/0961203393002001041 · Cited by 111
The Cardiovascular Burden of Lupus
Schattner, A., & Liang, M. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.13.1507 · Cited by 59
Contributions of Observational Cohort Studies in Systemic Lupus Erythematosus: The University of Toronto Lupus Clinic Experience
Urowitz, M. B., & Gladman, D. D. (2005) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2005.01.008 · Cited by 59
Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis, or thoracolumbar spine
Hansen, E., Jessing, P., Lindewald, H., Østergaard, P., Olesen, T., & Malver, E. (1976) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-197658080-00008 · Cited by 27
Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus
Martínez-Berriotxoa, A., Ruiz‐Irastorza, G., Egurbide, M.-V., Rueda, M., & Aguirre, C. (2004) · Lupus · doi:10.1191/0961203304lu2035oa · Cited by 26
Self-citation
Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies
Ho (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200110)44:10 · Cited by 3
Untitled work
(1999) · doi:10.1002/1529-0131(199901)42:1
Untitled work
Wilson (1999) · doi:10.1002/1529-0131(199907)42:7

Flagged first, then by citations

Research works printed but not linked: 3

Rosembaum PR , Rubin DB. The central role of propensity scores in estimating dose-response functions . Biometrika 1983; 70: 41-55 .
10.1177/0961203396005001031 · DOI · Paper page
Alarcón GS , McGwin G, Jr. , Fessler BJ et al. “Confounding by indications” partially explains the protective effect of hydroxychloroquine (HCQ) in SLE survival: Data from a multiethnic US cohort . Arthritis Rheum 2005; 52: S726-S726 .

Sorted by citations

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,735
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
Self-citation
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramón, E., Buonaiuto, V, Jacobsen, S., Zeher, M. M., Tarr, T., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204838 · Cited by 974
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 818
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
van Vollenhoven, R., Mosca, M., Bertsias, G. K., Isenberg, D. A., Kuhn, A., Lerstrøm, K., Aringer, M., Bootsma, H., Boumpas, D., Bruce, I. N., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205139 · Cited by 761

See all 412

Authors: Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., Erdozain, J.-G., & Aguirre, C.
Affiliations: Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain,
University of the Basque Country (ES)
Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
ORCID: Pijoan, J-I
Erdozain, J-G
Venue: Lupus
Publisher: SAGE Publications
Published: 2006-09
Volume: 15
Issue: 9
Pages: 577-583
ISSN: 0961-2033 (ISSN-L)
1477-0962
DOI: 10.1177/0961203306071872
OpenAlex: W2014873778
Cited by: 411
References: 48
Citations by year: 2026: 11 · 2025: 7 · 2024: 30 · 2023: 24 · 2022: 19 · 2021: 22 · 2020: 29 · 2019: 23 · 2018: 27 · 2017: 17 · 2016: 18 · 2015: 20 · 2014: 28 · 2013: 22 · 2012: 25
FWCI: 11.16
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Lupus (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: antimalarial drugs, systemic lupus erythematosus, thrombosis, survival, antiphospholipid antibodies, cardiovascular complications, mortality, hydroxychloroquine, chloroquine
MeSH terms: Adult, Analysis of Variance, Antimalarials, Cause of Death, Female, Follow-Up Studies, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Prospective Studies, Research Design, Risk Factors, Spain, Thrombosis, Time Factors, Survival Rate, Proportional Hazards Models, Survival Analysis, Treatment Failure, Endpoint Determination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks